Author’s response to reviews

Title: Evaluation of Prophylactic Dosages of Enoxaparin in Non-Surgical Elderly Patients with Renal Impairment

Authors:

Nibal Chamoun (nibal.chamoun@lau.edu.lb)
Hady Ghanem (hady.ghanem@laumcrh.com)
Ahmad Hachem (ah220@aub.edu.lb)
Essa Hariri (Essa.Hariri@umassmed.edu)
Christelle Lteif (christelle.lteif@lau.edu)
Hanine Mansour (hanine.mansour@lau.edu.lb)
Hani Dimassi (hani.dimassi@lau.edu.lb)
Richard Zalloum (richard.zalloum@laumcrh.com)
Georges Ghanem (georges.ghanem@laumcrh.com)

Version: 3 Date: 20 Apr 2019

Author’s response to reviews:

April 20, 2019

Response Letter: BMC Pharmacy and Toxicology

Manuscript: PHAT-D-19-00040R2

Dear Mr. Matthew P. Hickey and Mr. William Spenceley Jones

Thank you for your email. Please find below my point by point response to the requested revisions.
1. Under your Ethics approval and consent to participate heading in the Declarations section, please clarify whether informed consent for participation had been obtained from participants. As of now the statement only addresses publication. When doing so, please clearly specify if consent had been written or verbal.

- On p.15, Lines 312-317, section Ethics approval and consent to participate

The following section was already included in the manuscript, however on line 317, I added the words: “participation and” before the word anonymized. The text now reads as:

- This study was approved by the Lebanese American University Institutional Review Board (LAU IRB), approval number is LAU.SOP.NC1.25/Jun/2015 and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from the patient(s) for their participation and anonymized information to be published in this article.

2. Please include the date of trial registration with the Trial registration number in the abstract.

- Abstract, p.3, line 60, I added the date of registration:

- The trial was retrospectively registered on ClinicalTrials.gov identifier: NCT03158792. Registered: May 18, 2017.

3. Please provide a List of abbreviations after the Conclusions section. If abbreviations are used in the text, they should be defined in the text at first use and included in this list.

- Thank you and my apologies for omitting the list of abbreviations.
- P.9 line 188, I defined ICU as Intensive care unit.
- P.9 line 190, I added the abbreviation CHF
- P.13, line 272, removed the abbreviation GFR and added glomerular filtration rate since it is only mentioned once in the document.
- P.14 line 285, I added the abbreviation CHF

Section List of abbreviations, p.15, lines 298-309 the list of abbreviations has been added

- VTE: Venous thromboembolism
- LMWHs: low molecular weight heparins
• CrCl: creatinine clearance
• SC: subcutaneously
• IBW: ideal body weight
• DVT: deep venous thrombosis
• PE: pulmonary embolism
• CRF: case Report Form
• ICU: intensive care unit
• CHF: congestive heart failure
• SrCr: serum creatinine

4. Please note that all authors should be named by using their initials rather than full names in the Authors’ contributions section. For example, author John Smith should be represented as JS in this section.

• Thank you for pointing this out, the changes have been made. Authors’ contributions section,

P. 16, Lines 330-343. This section now reads as:

• NC is responsible for study concept and design, participated in data collection, wrote the introduction and discussion sections of the manuscript, contributed to the abstract and results and is the guarantor of the manuscript, including the data and analysis.

• HG contributed substantially to the study design, data interpretation, writing of the manuscript, accuracy of the data analysis, including any adverse effects and contributed to editing the remaining sections of the manuscript.

• AH, EH and CL participated in the data collection, take responsibility for the integrity of the data, wrote the methods section and abstract, and contributed to the discussion and introduction.

• HD contributed to the study design, performed the statistical analysis, contributed to the methods and results sections, and contributed to editing the remaining sections of the manuscript.

• HM contributed to the study design, data collection, wrote the results section of the manuscript and contributed to editing the remaining sections of the manuscript.
• RZ and GG participated in data collection and contributed to editing the manuscript. All authors have read and approved the final manuscript.